Biotechnology - Neurological, Rare diseases

Filter

Current filters:

NeurologicalRare diseases

Popular Filters

Orphan status for Alexion's Solaris

16-07-2013

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says that Soliris (eculizumab), the company's first-in-class…

Alexion PharmaceuticalsBiotechnologyEuropeNeurologicalPharmaceuticalRare diseasesRegulationSolaris

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions

17-12-2012

French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Drug shortages spur developments in neurometabolic treatments

17-04-2012

A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top